Clinical trials: Viral Hepatitis
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Hepatitis C, Chronic
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
The purpose of this study is to assess the efficacy of a 12-week regimen containing simeprevir, daclatasvir and sofosbuvir in participants with decompensated liver disease (the liver function is insufficient) due to genotype 1 or…
- Trial name
- NCT02262728
- Testing
- Simeprevir, Daclatasvir, Sofosbuvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis C Virus
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
- Trial name
- NCT01740791
- Testing
- Velpatasvir
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Malaria, Malaria Vaccines
Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)
This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated…
- Trial name
- NCT01345240
- Testing
- GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix-B™ vaccine, Infanrix/Hib™ vaccine
- Where
- 2 sites in Burkina Faso, Ghana
- Volunteers
- 705 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with…
- Trial name
- NCT02536313
- Testing
- SOF/VEL/VOX, RBV
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
Hepatitis C, Opiate Dependence
Effective Treatment of Hepatitis C in Substance Users
We hypothesize that integrating Hepatitis C into methadone and buprenorphine treatment will improve Hepatitis C outcomes as well as drug treatment outcomes in patients who are addicted to opiates.
- Trial name
- NCT00633243
- Testing
- Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Liver Cirrhosis
Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
This trial was intended to investigate the pharmacokinetics, safety and tolerability of BI 201335 NA soft-gel capsules in patients with compensated liver cirrhosis, i.e. grade A according to Child-Pugh classification (< 7 points).
- Trial name
- NCT01909778
- Testing
- BI 201335
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
HIV Infection, Hepatitis C
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons…
- Trial name
- NCT01285050
- Testing
- Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.
- Trial name
- CERTAIN-2 (NCT02723084)
- Testing
- ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV)
- Volunteers
- 136 people
- Sponsor
- AbbVie
Hepatitis C Infection, HIV
HCV-HIV Co-infected Patient Cohort in Thailand
This is a study of HCV treatment using the standard regimen of pegylated-interferon plus ribavirin in HIV co-infected patients participating in the PHPT cohort study.
- Trial name
- NCT02247440
- Testing
- Peg-interferon + ribavirin under HIV physician supervision
- Where
- 5 sites in Thailand
- Volunteers
- 18 people
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with…
- Trial name
- NCT02781558
- Testing
- SOF/VEL, RBV
- Where
- 28 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants…
- Trial name
- NCT00703118
- Testing
- Telaprevir, Peg-IFN-alfa-2a, Ribavirin
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 663 people
- Sponsor
- Tibotec BVBA
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus…
- Trial name
- NCT02249182
- Testing
- LDV/SOF, RBV
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Hepatitis
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
The purpose of this study is to evaluate daclatasvir in combination with sofosbuvir given to children with chronic hepatitis C infection
- Trial name
- NCT03487848
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 2 sites in Australia, Spain
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C, Chronic, Hepatitis C Virus
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
- Trial name
- NCT00705224
- Testing
- Pegylated Interferon, Ribavirin
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Virus (HBV)
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT00734162
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- 21 sites in United States, Bulgaria and 5 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as…
- Trial name
- NCT02455167
- Testing
- Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.